The updated Medscheme specialised drug list for 2023 has been published

By HEOR Staff Writer

May 12, 2023

Reimbursement is still dependent on authorisation and benefit limits.

Some drugs included:
ANTIHEMORRHAGICS
Hemlibra

CARDIOVASCULAR SYSTEM
Volibris

DERMATOLOGICALS
Dupixent

ANTIVIRALS FOR SYSTEMIC USE
Epclusa

ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy

IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair

Reference url

Recent Posts

Advancing Kidney Transplant Transparency Through Patient Involvement

By HEOR Staff Writer

November 6, 2025

Enhancing Kidney Transplant Transparency In a
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Efficiency

By HEOR Staff Writer

November 5, 2025

UK Clinical Trial Reforms Slash Approval Times UK Clinical Trial Reforms have accelerated clinical trial approvals, reducing average times from 91 days to 41 days through risk-proportionate changes at the Medicines and Healthcare produ...
AI in South African Healthcare: Professionals’ Confidence in Reducing Admissions and Enhanc...

By HEOR Staff Writer

AI Optimism in South Africa's Healthcare Landscape AI in South African Healthcare is gaining momentum, as evidenced by the Philips Future Health Index (FHI...